In Canada in 2000, a previously unrecognized adverse event, called oculorespiratory syndrome (ORS), was identified in association with the influenza vaccine. Oculorespiratory syndrome was characterized by bilateral red eyes, and/or respiratory symptoms, and/or facial edema, occurring within a few hours of influenza immunization and generally resolving within 48 hours. During that year, ORS was associated mostly with one manufacturer’s vaccine, but the following year, ORS was reported to occur with both manufacturers’ vaccines marketed in Canada. In this randomized placebo-controlled crossover trial, De Serres and colleagues assessed the safety of revaccination in patients affected by ORS in 2000 or 2001 and found that patients who sustained ORS in 2000 and were not revaccinated had a high risk of recurrence when given the 2002-2003 formulation of the vaccine initially associated with ORS. For the second vaccine and for patients who had ORS in 2000 who had been revaccinated the year before or those who had ORS in 2001, the risk of recurrence was much lower. Most recurrences were mild: 86% of patients rated severity as mild (bothersome but did not interfere with daily activities) and nearly all (94%) said they would be revaccinated the following year. Vaccine providers should reassure patients affected by ORS that this experience is not a contraindication to revaccination.